Illumina (NASDAQ:ILMN) Price Target Raised to $140.00 at JPMorgan Chase & Co.

Illumina (NASDAQ:ILMN) had its price target upped by JPMorgan Chase & Co. from $125.00 to $140.00 in a research note published on Tuesday,Benzinga reports. They currently have a neutral rating on the life sciences company’s stock.

Other analysts also recently issued research reports about the stock. TD Cowen raised shares of Illumina from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $126.00 to $144.00 in a report on Wednesday, August 14th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $120.00 to $154.00 in a report on Friday, August 16th. Citigroup boosted their price objective on shares of Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Canaccord Genuity Group boosted their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $162.18.

Illumina Trading Down 2.6 %

NASDAQ ILMN opened at $151.09 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 0.86 and a current ratio of 2.43. The firm has a market cap of $24.07 billion, a PE ratio of -15.17 and a beta of 1.13. Illumina has a one year low of $89.00 and a one year high of $156.66. The firm’s fifty day moving average is $138.09 and its two-hundred day moving average is $123.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the business posted $0.33 earnings per share. The business’s revenue was down 3.5% compared to the same quarter last year. Analysts expect that Illumina will post 4.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ILMN. First Trust Direct Indexing L.P. acquired a new position in shares of Illumina during the first quarter valued at $229,000. Norden Group LLC bought a new position in Illumina during the first quarter valued at about $584,000. Private Advisor Group LLC boosted its stake in Illumina by 4.8% during the first quarter. Private Advisor Group LLC now owns 4,955 shares of the life sciences company’s stock valued at $679,000 after buying an additional 226 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Illumina by 41.5% during the first quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company’s stock valued at $422,000 after buying an additional 900 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in Illumina by 5.8% during the first quarter. Nordea Investment Management AB now owns 14,382 shares of the life sciences company’s stock valued at $1,981,000 after buying an additional 784 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.